3种用药方案治疗2型糖尿病的数据包络分析  

Data Envelopment Analysis of Three Therapy Schemes in the Treatment of Type 2 Diabetes

作　　者：张正升[1] 何争民 陈进[1] 刘秀珍[1] 

机构地区：[1]安徽合肥市第二人民医院,合肥230031

出　　处：《海峡药学》2015年第8期83-85,共3页Strait Pharmaceutical Journal

摘　　要：目的评价3种用药方案治疗2型糖尿病的数据包络分析。方法 96名患者分为3组,分别给予二甲双胍肠溶片联合磺脲类药物(A组32人)、阿卡波糖联合甘精胰岛素组(甘精胰岛素,B组29人)、预混胰岛素组(精蛋白重组人胰岛素M30,C组35人)治疗1年,期间每3个月随访1次。以医疗成本为投入,空腹血糖(FBG),餐后2h血糖(PBG2H),糖化血红蛋白(Hb Alc%),质量调整生命年(QALYs)为产出,使用数据包络分析(DEA)对投入和产出进行经济学综合评价。结果数据包络分析结果显示C组投入和产出的配比达到最优,A组、B组投入成本偏高且临床疗效有待提高,QALYs值A组有待提高,B组获得的已达到理想值。结论 3种治疗方案中预混胰岛素方案更加经济有效。OBJECTIVE To evaluate the DEA of three therapy schemes in the treatment of type 2 diabe-tes.METHODS A total of 96 patients were enrolled and randomized to Group A （ metformin＋sulfonylureas 32 ） , Group B （ acarbose＋Insulinglargineinjection 29 ） or Group C （ protamine zinc recombinant human insulin M30 35 ） .The DEA of the 3 groups was evaluated after treatment for 1 year with clinical randomized trial were followed up.The medical costs of inputs,fasting blood glucose （FBG）,2h postprandial blood glucose （2hPG）,glycosylated hemoglobin （ HbAlc%） ,quality adjusted life years （ QALYs） as the output,using data envelopment analysis （ DEA） comprehensive evaluation of the economics of input and output.RESULTS DEA results showed that the group C input and output achievd optimal.A and B group investment cost was higher and the clinical curative effect was to be improved.QALYs of A group needed to be improved, B group had reached the ideal value.CONCLUSION Premixed insulin therapy has a better clinical effect and economic effect.

关 键 词：数据包络分析法 治疗方案 2型糖尿病 

分 类 号：R969.4[医药卫生—药理学]